Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease

Clinical Neuropharmacology

Volumn 28, Issue 5, 2005, Pages 238-240

  Müller, Thomas ^a   Lang, Undine E ^b   Muhlack, Siegfried ^a   Welnic, Jacub ^a   Hellweg, Rainer ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Levodopa; Nerve growth factor; Parkinson disease

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; LEVODOPA; NERVE GROWTH FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG PROTEIN BINDING; FEMALE; HUMAN; MALE; NERVE GROWTH; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIPARKINSON AGENTS; AREA UNDER CURVE; BENSERAZIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; PARKINSON DISEASE;

EID: 27644533548     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000183447.58529.79     Document Type: Article

References (15)

1. Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm. 2004;111:201-216.
2. Okuma Y, Hattori N, Mizuno Y. Sensory neuropathy in autosomal recessive juvenile parkinsonism (PARK2). Parkinsonism Relat Disord. 2003;9:313-314.
3. Lorigados PL, Pavon FN, Alvarez GL, et al. Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Res. 2002; 952:122-127.
4. Ohta M, Mizuta I, Ohta K, et al. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun. 2000;272:18-22.
5. Müller T, Renger K, Kuhn W. Levodopa associated homocysteine increase and sural axonal neurodegeneration. Arch Neurol. 2004;61:657-660.
6. Lang UE, Gallinat J, Danker-Hopfe H, et al. Nerve growth factor serum concentrations in healthy human volunteers: physiological variance and stability. Neurosci Lett. 2003;344:13-16.
7. Mizuta I, Ohta M, Ohta K, et al. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun. 2000;279:751-755.
8. Ohta K, Fujinami A, Kuno S, et al. Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology. 2004;71:162-168.
9. Semkova I, Wolz P, Schilling M, et al. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol. 1996;315:19-30.
10. Müller T, Woitalla D, Kuhn W. Benefit of folic acid supplementation in parkinsonian patients treated with levodopa. J Neurol Neurosurg Psychiatry. 2003;74:549.
11. Zhao WQ, Williams Z, Shepherd KR, et al. S-adenosyl-methionine-induced apoptosis in PC12 cells. J Neurosci Res. 2002;69:519-529.
12. Cimato TR, Ettinger MJ, Zhou X, et al. Nerve growth factor-specific regulation of protein methylation during neuronal differentiation of PC12 cells. J Cell Biol. 1997;138:1089-1103.
13. Maswood N, Young J, Tilmont E, et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci USA. 2004;101:18171-18176.
14. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol. 1998;43:561-575.
15. St-Hilaire M, Landry E, Levesque D, et al. Denervation and repeated L-dopa induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats. Neurobiol Dis. 2003;14:98-109.